SCHEMBL27873273

SCHEMBL27873273

CCCCC(=O)ONC(=O)c1cccnc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 2/20 0.58
▸ HDAC3 O15379 1/20 0.58
▸ HDAC2 Q92769 1/20 0.58
▸ L3MBTL1 Q9Y468 1/20 0.53
▸ LMNA P02545 3/20 0.51
▸ MAPT P10636 1/20 0.50
▸ GAA P10253 1/20 0.50
▸ CYP1A2 P05177 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ TSHR P16473 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ THRB P10828 1/20 0.49
▸ HDAC6 Q9UBN7 1/20 0.49
▸ ALDH1A1 P00352 2/20 0.48
▸ HTT P42858 1/20 0.48
▸ KMT2A Q03164 3/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ NPC1 O15118 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27889653 0.92 HDAC1 (0.53) HDAC1HDAC3HDAC2L3MBTL1LMNA
SCHEMBL27889580 0.92 HDAC1 (0.54) HDAC1HDAC3HDAC2LMNACYP1A2
SCHEMBL21082071 0.86 HDAC1 (0.54) HDAC1HDAC3HDAC2LMNAMAPT
SCHEMBL21793728 0.85 TBXAS1 (0.53) —
SCHEMBL27367994 0.83 ALDH1A1 (0.54) HDAC1HDAC3HDAC2MAPTHDAC6
SCHEMBL11129975 0.79 NAAA (0.54) HDAC1HDAC3HDAC2MAPTHDAC6
SCHEMBL15993619 0.77 NAAA (0.56) HDAC1HDAC3HDAC2MAPTHDAC6
SCHEMBL9565915 0.77 ALDH1A1 (0.59) HDAC1HDAC3HDAC2LMNAMAPT
SCHEMBL31030252 0.76 HDAC1 (0.63) HDAC1HDAC3HDAC2L3MBTL1LMNA
SCHEMBL552456 0.76 HDAC1 (0.63) HDAC1HDAC3HDAC2L3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102712595-B Novel compositions for reducing A beta 42 production and their use in treating alzheimer's disease (AD) KAREUS THERAPEUTTICS SA 2015-04-22 — — CN disclosed
CN-102712595-A Novel compositions for reducing A beta 42 production and their use in treating alzheimer's disease (AD) KAREUS THERAPEUTTICS SA 2012-10-03 — — CN disclosed
Send feedback